@xconomy.com 3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com 4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com 5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com 5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com 5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com 5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@techcrunch.com 6 years ago
Mendel.ai nabs $2 million to match cancer patients with the latest clinical trials